Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for severe eczema sufferers

NCT ID NCT07217015

Disease control Sponsor: Kymera Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up open-label period of 52 weeks, and involves about 200 participants.

Why investors are watching

Kymera Therapeutics is testing KT-621, an oral drug for moderate to severe atopic dermatitis (eczema), in a phase 2b trial with 200 participants. For a small company, this readout is a key test of whether the drug works and is safe enough to advance. A clear result could shape the company's value and its next steps.

If it works: If KT-621 reduces eczema severity and extent better than placebo with acceptable safety, Kymera could move the drug toward later-stage trials. That outcome would support the drug's potential as a convenient oral option for a common skin condition.

If it fails: Phase 2 trials often fail to show a clear benefit over placebo. A weak result or safety problem could delay or end KT-621's development, leaving Kymera without a major pipeline candidate.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be 12 to 75 years of age, inclusive, at the time of signing the IAF (informed assent form) and/or ICF (informed consent form). * Must have chronic AD that has been present for at least 3 years (for participants ≥ 18 years of age) or 1 year (for participants \< 18 years of age) before the Screening visit. * Must have an EASI score ≥ 16 at the Screening and Baseline visits. * Must have a vIGA-AD score ≥ 3 (scale of 0 to 4) at the Screening and Baseline visits. * Must have at least 10% BSA of AD involvement at the Screening and Baseline visits. * Must have a weekly average Peak Pruritus NRS value ≥ 4 at the Baseline visit. * Must have a history within the 6 months prior to the Baseline visit of either an inadequate response to, or inability to take, topical medications for the treatment of AD. * Must apply a stable dose of moisturizer at least twice daily for at least 7 consecutive days immediately prior to the Baseline visit. Participants should be willing to continue using moisturizer twice daily during the study. * Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol. * Must agree to contraceptive requirements in compliance with the clinical study and local requirements. Exclusion Criteria: * Must not have an unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the Investigator in the 4 weeks before the baseline visit. * Must not have other skin conditions, such as contact dermatitis, psoriasis, tinea corporis, or lupus erythematosus, that may interfere with study assessments. * Must not have a clinically relevant history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, ophthalmological, or connective tissue diseases or disorders. * Must not have any surgical or medical procedure planned during participation in the study. * Must not have a history of alcohol or substance abuse within the previous 2 years. * Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study. * Must not have a history of lack of response to any medication targeting interleukin (IL)-4, IL-13, and/or janus kinase (JAK)- signal transducer and activator of transcription (STAT) pathways (e.g. dupilumab, tralokinumab, upadacitinib, abrocitinib) at approved doses after at least 16 weeks of therapy. * Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening. * Must not have been dosed with any investigational drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration. * Female participants of childbearing potential must not have a positive or undetermined pregnancy result at the Screening and baseline visits. * Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results. * Must not be taking or have taken any prespecified prohibited therapies within a specific timeframe as evaluated by the Investigator. * Must not have a known sensitivity to any of the components of KT-621. * Must not be a member of the investigational team or his/her immediate family.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Kymera Investigative Site

    Ann Arbor, Michigan, 48103, United States

  • Kymera Investigative Site

    Detroit, Michigan, 48202, United States

  • Kymera Investigative Site

    The Bronx, New York, 10455, United States

  • Kymera Investigative Site

    Fargo, North Dakota, 58103, United States

  • Kymera Investigative Site

    Portland, Oregon, 97201, United States

  • Kymera Investigative Site

    Portland, Oregon, 97239, United States

  • Kymera Investigative Site

    Philadelphia, Pennsylvania, 19103, United States

  • Kymera Investigative Site

    San Antonio, Texas, 78213, United States

  • Kymera Investigative Site

    San Antonio, Texas, 78218, United States

  • Kymera Investigative Site

    Darlinghurst, New South Wales, Australia

  • Kymera Investigative Site

    Kogarah, New South Wales, Australia

  • Kymera Investigative Site

    Brisbane, Queensland, Australia

  • Kymera Investigative Site

    Woolloongabba, Queensland, Australia

  • Kymera Investigative Site

    Melbourne, Victoria, Australia

  • Kymera Investigative Site

    Calgary, Alberta, Canada

  • Kymera Investigative Site

    Edmonton, Alberta, Canada

  • Kymera Investigative Site

    Kelowna, British Columbia, Canada

  • Kymera Investigative Site

    Surrey, British Columbia, Canada

  • Kymera Investigative Site

    Markham, Ontario, Canada

  • Kymera Investigative Site

    Ottawa, Ontario, Canada

  • Kymera Investigative Site

    Richmond Hill, Ontario, Canada

  • Kymera Investigative Site

    Toronto, Ontario, Canada

  • Kymera Investigative Site

    Windsor, Ontario, Canada

  • Kymera Investigative Site

    Québec, Quebec, Canada

  • Kymera Investigative Site

    Pardubice, Czechia

  • Kymera Investigative Site

    Prague, Czechia

  • Kymera Investigative Site

    Augsburg, Bavaria, Germany

  • Kymera Investigative Site

    München, Bavaria, Germany

  • Kymera Investigative Site

    Bad Bentheim, Germany

  • Kymera Investigative Site

    Berlin, Germany

  • Kymera Investigative Site

    Dresden, Germany

  • Kymera Investigative Site

    Frankfurt, Germany

  • Kymera Investigative Site

    Friedrichshafen, Germany

  • Kymera Investigative Site

    Mainz, Germany

  • Kymera Investigative Site

    Münster, Germany

  • Kymera Investigative Site

    Ichikawa, Chiba, Japan

  • Kymera Investigative Site

    Kagoshima, Japan

  • Kymera Investigative Site

    Kanagawa, Japan

  • Kymera Investigative Site

    Nagoya, Japan

  • Kymera Investigative Site

    Osaka, Japan

  • Kymera Investigative Site

    Sakai, Japan

  • Kymera Investigative Site

    Sapporo, Japan

  • Kymera Investigative Site

    Chorzów, Poland

  • Kymera Investigative Site

    Gdansk, Poland

  • Kymera Investigative Site

    Gdynia, Poland

  • Kymera Investigative Site

    Krakow, Poland

  • Kymera Investigative Site

    Lublin, Poland

  • Kymera Investigative Site

    Rzeszów, Poland

  • Kymera Investigative Site

    Szczecin, Poland

  • Kymera Investigative Site

    Warsaw, Poland

  • Kymera Investigative Site

    Wroclaw, Poland

  • Kymera Investigative Site

    Ansan-si, South Korea

  • Kymera Investigative Site

    Cheonan, South Korea

  • Kymera Investigative Site

    Gyeonggi-do, South Korea

  • Kymera Investigative Site

    Incheon, South Korea

  • Kymera Investigative Site

    Seoul, South Korea

  • Kymera Investigative Site

    Birmingham, Alabama, 35244, United States

  • Kymera Investigative Site

    North Little Rock, Arkansas, 72117, United States

  • Kymera Investigative Site

    Freemont, California, 94538, United States

  • Kymera Investigative Site

    Los Angeles, California, 90025, United States

  • Kymera Investigative Site

    Los Angeles, California, 90045, United States

  • Kymera Investigative Site

    Santa Monica, California, 91350, United States

  • Kymera Investigative Site

    Delray Beach, Florida, 33484, United States

  • Kymera Investigative Site

    Jacksonville, Florida, 32256, United States

  • Kymera Investigative Site

    Miami, Florida, 33137, United States

  • Kymera Investigative Site

    Miramar, Florida, 33027, United States

  • Kymera Investigative Site

    Normal, Illinois, 61761, United States

  • Kymera Investigative Site

    Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.